Abbott Completes $21 Billion Exact Sciences Acquisition, Bolstering Cancer Diagnostics
ABT is trading near its 52-week low of $105.27 (1.8% above the low) on elevated volume (7.5× avg).
Summary
Abbott Laboratories has completed its significant $21 billion acquisition of Exact Sciences, paying $105 per share. This strategic move, which was funded by a recent $20 billion senior notes offering and outlined in the company's 2025 annual report, positions Abbott as a leader in cancer screening and precision oncology diagnostics. The acquisition adds key products like Cologuard and Oncotype DX, establishing a new growth vertical for Abbott. This is a highly material event for the company, significantly expanding its market footprint and future revenue potential in a critical healthcare segment. Investors will now watch for details on the integration process and the financial contributions of the acquired assets.
At the time of this announcement, ABT was trading at $107.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $183.3B. The 52-week trading range was $105.27 to $139.06. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.